NeuroVive and Yungjin reports positive KL1333 phase I clinical study results paving the way for further clinical development
Lund, Sweden and Seoul, Korea, 21 May 2018 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly an ...